MorphoSys AG
NASDAQ:MOR

Watchlist Manager
MorphoSys AG Logo
MorphoSys AG
NASDAQ:MOR
Watchlist
Price: 18.96 USD 2.43% Market Closed
Market Cap: 2.9B USD

Relative Value

There is not enough data to reliably calculate the relative value of MOR.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MOR Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
12.5
Median 5Y
9.7
Industry
8
Forward
10.8
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-5.5
Industry
23.5
Forward
-15.3
vs History
vs Industry
Median 3Y
-8.5
Median 5Y
-4.3
Industry
21.9
vs History
vs Industry
Median 3Y
-8.2
Median 5Y
-2.4
Industry
24.3
vs History
vs Industry
Median 3Y
-9.7
Median 5Y
-6.2
Industry
3.2
vs History
vs Industry
Median 3Y
10.6
Median 5Y
6.2
Industry
8.1
Forward
9.2
vs History
vs Industry
Median 3Y
12.6
Median 5Y
7.5
Industry
10.1
vs History
vs Industry
Median 3Y
-5
Median 5Y
-3.7
Industry
5.9
Forward
-13.6
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-3.6
Industry
6.2
Forward
-11.3
vs History
vs Industry
Median 3Y
-7.2
Median 5Y
-2.9
Industry
7.7
vs History
vs Industry
Median 3Y
-7.2
Median 5Y
-3.7
Industry
6.3
vs History
vs Industry
Median 3Y
1.9
Median 5Y
1.9
Industry
5.6

Multiples Across Competitors

MOR Competitors Multiples
MorphoSys AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
MorphoSys AG
NASDAQ:MOR
2.5B USD 12.4 -5.5 -5 -4.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 845 618.3 -160 863.2 -195 339.2 -193 110.2
US
Abbvie Inc
NYSE:ABBV
405.4B USD 6.8 172.6 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
175.8B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
151.3B USD 5.2 18.7 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 081.5 -531.1 -578.4 -562.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.7B USD 5.7 17.9 17 19.3
AU
CSL Ltd
ASX:CSL
83.3B AUD 3.6 18.6 12.6 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53B USD 16.5 1 216.4 164 198.9
NL
argenx SE
XBRU:ARGX
43.8B EUR 14.2 33.5 57.7 59.3
P/S Multiple
Revenue Growth P/S to Growth
DE
MorphoSys AG
NASDAQ:MOR
Average P/S: 3 077 070.8
12.4
24%
0.5
FR
Pharnext SCA
OTC:PNEXF
33 845 618.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 081.5
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.5
46%
0.4
NL
argenx SE
XBRU:ARGX
14.2
49%
0.3
P/E Multiple
Earnings Growth PEG
DE
MorphoSys AG
NASDAQ:MOR
Average P/E: 191.7
Negative Multiple: -5.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 863.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.7
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
10%
1.8
AU
CSL Ltd
ASX:CSL
18.6
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 216.4
N/A N/A
NL
argenx SE
XBRU:ARGX
33.5
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DE
MorphoSys AG
NASDAQ:MOR
Average EV/EBITDA: 40.2
Negative Multiple: -5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 339.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
164
N/A N/A
NL
argenx SE
XBRU:ARGX
57.7
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DE
MorphoSys AG
NASDAQ:MOR
Average EV/EBIT: 46.4
Negative Multiple: -4.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 110.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -562.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198.9
N/A N/A
NL
argenx SE
XBRU:ARGX
59.3
N/A N/A